Antiandrogen gold nanoparticles dual-target and overcome treatment resistance in hormone-insensitive prostate cancer cells.
about
The role of androgens in metabolism, obesity, and diabetes in males and femalesTargeting the androgen receptor with steroid conjugatesNanomedicine therapeutic approaches to overcome cancer drug resistanceNanomaterials for reversion of multidrug resistance in cancer: a new hope for an old idea?Gold nanoparticles for cancer radiotherapy: a reviewThe optical, photothermal, and facile surface chemical properties of gold and silver nanoparticles in biodiagnostics, therapy, and drug deliveryP-glycoprotein-dependent trafficking of nanoparticle-drug conjugatesStructural and Functional Evidence for Testosterone Activation of GPRC6A in Peripheral TissuesUtilisation of nanoparticle technology in cancer chemoresistance.Size effect of Au/PAMAM contrast agent on CT imaging of reticuloendothelial system and tumor tissue.Selectively targeting prostate cancer with antiandrogen equipped histone deacetylase inhibitors.Inorganic Nanocarriers Overcoming Multidrug Resistance for Cancer Theranostics.Receptor-based targeting of therapeutics.The GPCR, class C, group 6, subtype A (GPRC6A) receptor: from cloning to physiological function.Advances in targeting strategies for nanoparticles in cancer imaging and therapy.Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistanceThe application of gold nanoparticles as a promising therapeutic approach in breast and ovarian cancer.Cellular uptake of nanoparticles: journey inside the cell.N-glycosylation and disulfide bonding affects GPRC6A receptor expression, function, and dimerization.Design, synthesis, and evaluation of the antiproliferative activity of hydantoin-derived antiandrogen-genistein conjugates.Gender differences in glucose homeostasis and diabetes.In vitro/in vivo "peeling" of multilayered aminocarboxylate gold nanoparticles evidenced by a kinetically stable 99mTc-label.Skin Cancer and Its Treatment: Novel Treatment Approaches with Emphasis on Nanotechnology
P2860
Q26824343-3E086CB3-FB09-4B9D-A56A-E62863F78918Q26995692-361BE573-BACE-4D0B-97EE-51BFA432056EQ27011692-CDDBEC6B-89D6-4BAC-8EC0-6FDA976E9329Q27500424-16021011-2C77-4C3F-8387-EC274AD850BFQ28066413-FF4823F6-D65D-4C81-A9B4-BDEB37510156Q28392595-F977CF0B-7965-43CE-9944-A046CCCB6BADQ34062299-2F074558-D37D-4172-8F01-42E91699227FQ36331791-A48455EE-9A1B-4CBE-853F-2B75E9B913BDQ36421258-7449C911-1973-4DC9-9D1F-1593B1DA9E89Q37284538-99DE5DAC-395D-4419-B6C8-4BDD7BAD6D7DQ37332601-91645620-0D79-4081-B6AA-8D2C0AAA7050Q37404658-FD301DE4-EFEE-482F-AA5C-0DADD14EC69AQ38084739-9E526044-15D6-4C0E-BD8C-5C39FCB173D8Q38137171-D673553B-3D80-4756-8375-FB8C7ED90263Q38255901-5A43BEDD-F9C4-47A7-B903-B01D6A4440BBQ38410885-4170C4A1-5809-4E04-B3CB-19B641F19EF4Q38419992-D7DDE940-9178-48DD-B4F8-07598D6C83DFQ38557482-070195E2-7E0C-4A2F-8498-68BCEB5DB2A6Q41532436-A2F779EB-8E17-43C1-8C6A-C039B80F162AQ49886681-F87FDA96-A64F-43F6-B672-3A71889F96B4Q51256741-0384A965-E757-4020-AFF5-F3425FE84751Q52772046-5375687E-F17B-44BD-BC46-14291BA7DA1CQ57370671-A64ACA58-38BB-4E3F-A50F-A53A897366DA
P2860
Antiandrogen gold nanoparticles dual-target and overcome treatment resistance in hormone-insensitive prostate cancer cells.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Antiandrogen gold nanoparticle ...... nsitive prostate cancer cells.
@ast
Antiandrogen gold nanoparticle ...... nsitive prostate cancer cells.
@en
type
label
Antiandrogen gold nanoparticle ...... nsitive prostate cancer cells.
@ast
Antiandrogen gold nanoparticle ...... nsitive prostate cancer cells.
@en
prefLabel
Antiandrogen gold nanoparticle ...... nsitive prostate cancer cells.
@ast
Antiandrogen gold nanoparticle ...... nsitive prostate cancer cells.
@en
P2093
P2860
P50
P356
P1476
Antiandrogen gold nanoparticle ...... ensitive prostate cancer cells
@en
P2093
Adegboyega K Oyelere
Brice A Tene Defo
Mostafa A El-Sayed
Steven C Hayden
P2860
P304
P356
10.1021/BC300158K
P577
2012-07-12T00:00:00Z